Last week, Flibanserin -- or "Addyi" -- became the first FDA-approved drug aimed at treating sexual dysfunction in women, quickly picking up the nickname: "the female Viagra." But that's not quite right. And though it's been marketed as a long overdue triumph for sexual equality, there are plenty of skeptics. Seeking to understand the nebulous world of prescription drugs and female desire, Brooke spoke this week with:
- Sally Greenberg, Executive Director of the National Consumers League, Member of Even the Score
- Thea Cacchioni, Assistant Professor in Women's Studies at the University of Victoria
- Dr. Susan F. Wood, Director of the Jacobs Institute of Women's Health at George Washington University, former Assistant Commissioner for Women's Health at the FDA
- Dr. Sheryl Kingsberg, clinical psychologist and Professor at Case Western Reserve School of Medicine
- Dr. Lori Brotto, Associate Professor in the Department of Obstetrics and Gynaecology at the University of British Columbia
Song: "You've Come A Long Way, Baby!" - Virginia Slims jingle